A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This is a single center, open-label, phase I study to evaluate the safety and preliminary
efficacy of MRx0518 with preoperative hypofractionated radiation in 15 patients with
resectable pancreatic cancer.
Subjects will take MRx0518 daily for one week prior to the start of radiation therapy,
throughout radiation and until surgical resection of the tumour.